Indo Pacific Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-06-2024
- Paid Up Capital ₹ 0.10 M
as on 21-06-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 3.94%
(FY 2019)
- Profit -2.82%
(FY 2019)
- Ebitda 5.98%
(FY 2019)
- Net Worth 16.92%
(FY 2019)
- Total Assets 3.36%
(FY 2019)
About Indo Pacific Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Awadhesh Mishra and Prashant Mishra serve as directors at the Company.
- CIN/LLPIN
U74120UP2016PTC077093
- Company No.
077093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Indo Pacific Pharma Private Limited offer?
Indo Pacific Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Sexual Wellness Products, Erectile Dysfunction Medicine, Anti Infective Drugs & Medicines, Malaria Medicine, Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs.
Who are the key members and board of directors at Indo Pacific Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Awadhesh Mishra  | Director | 11-Mar-2016 | Current |
| Prashant Mishra | Director | 11-Mar-2016 | Current |
Financial Performance of Indo Pacific Pharma.
Indo Pacific Pharma Private Limited, for the financial year ended 2019, experienced modest growth in revenue, with a 3.94% increase. The company also saw a slight decrease in profitability, with a 2.82% decrease in profit. The company's net worth Soared by an impressive increase of 16.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indo Pacific Pharma?
In 2019, Indo Pacific Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indo Pacific Pharma?
Unlock and access historical data on people associated with Indo Pacific Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indo Pacific Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indo Pacific Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
